Início › Câncer de Fígado (Carcinoma Hepatocelular) › Washington
Ensaios clínicos de Câncer de Fígado (Carcinoma Hepatocelular) em Washington
15 estudos para Câncer de Fígado (Carcinoma Hepatocelular) estão buscando participantes em locais em Washington.
Cidades em Washington
Texto oficial do estudo (Inglês)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
RecrutandoVoluntários saudáveis bem-vindos
Idades de 45 a 75 · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT06995898Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center- Montlake, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07227012A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0083, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07291076GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Fred Hutchinson Cancer Center, University of Washington, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Seattle
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06921785A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Wenatchee Valley Hospital and Clinics, Wenatchee
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- University of Washington School of Medicine, Seattle
RecrutandoFase 2
Idades 8 e acima · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Recrutando
Idades de 18 a 75 · Todos os sexos · Atualizado em 17 de jun. de 2026 · NCT05486572DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA09-0, Puyallup
- USA07-0, Spokane
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de mai. de 2026 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Virginia Mason Medical Center, Seattle
- Summit Cancer Centers - North Spokane, Spokane
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 27 de abr. de 2026 · NCT05440708Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- American Oncology Network Vista Oncology Division/Physician Partner Associate, Olympia
- Northwest Medical Specialties PLLC (NWMS), Tacoma
RecrutandoFase 1
Idades de 18 a 65 · Todos os sexos · Atualizado em 16 de mar. de 2026 · NCT07176650Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
- Seattle Children's Hospital, Seattle
RecrutandoFase 1
Idades de 1 a 26 · Todos os sexos · Atualizado em 17 de fev. de 2026 · NCT07148050A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 105, Spokane
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 21 de nov. de 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.